Compare Stocks: CELU, HURA, IMDX, and INO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.38	$1.07	$0.56 ▼ $2.55	$39.95M	0.79	446,922 shs	160,877 shs
HURA TuHURA Biosciences	$2.10	$2.14	$0.41 ▼ $3.43	$133.83M	-0.02	183,408 shs	149,262 shs
IMDX Oncocyte	$3.92	$4.34	$2.42 ▼ $8.51	$128.26M	1.8	240,256 shs	313,503 shs
INO Inovio Pharmaceuticals	$1.18	$1.10	$0.56 ▼ $2.72	$122.01M	1.63	2.95 million shs	2.25 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	+5.34%	-12.66%	+127.61%	-38.67%
HURA TuHURA Biosciences	0.00%	0.00%	-0.47%	-8.30%	-14.63%
IMDX Oncocyte	0.00%	-2.00%	-5.08%	-27.68%	+391,999,900.00%
INO Inovio Pharmaceuticals	0.00%	-4.84%	-8.53%	+5.36%	-52.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.38	$1.07	$0.56 ▼ $2.55	$39.95M	0.79	446,922 shs	160,877 shs
HURA TuHURA Biosciences	$2.10	$2.14	$0.41 ▼ $3.43	$133.83M	-0.02	183,408 shs	149,262 shs
IMDX Oncocyte	$3.92	$4.34	$2.42 ▼ $8.51	$128.26M	1.8	240,256 shs	313,503 shs
INO Inovio Pharmaceuticals	$1.18	$1.10	$0.56 ▼ $2.72	$122.01M	1.63	2.95 million shs	2.25 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	+5.34%	-12.66%	+127.61%	-38.67%
HURA TuHURA Biosciences	0.00%	0.00%	-0.47%	-8.30%	-14.63%
IMDX Oncocyte	0.00%	-2.00%	-5.08%	-27.68%	+391,999,900.00%
INO Inovio Pharmaceuticals	0.00%	-4.84%	-8.53%	+5.36%	-52.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	1.00	Sell	N/A	N/A
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	328.57% Upside
IMDX Oncocyte	2.33	Hold	$10.50	167.86% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	168.36% Upside

Current Analyst Ratings Breakdown

Latest CELU, HURA, IMDX, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	IMDX Oncocyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/18/2026	IMDX Oncocyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.50	N/A	N/A	($1.32) per share	-1.05
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
IMDX Oncocyte	$4.05M	31.67	N/A	N/A	($1.10) per share	-3.56
INO Inovio Pharmaceuticals	$60K	2,033.53	N/A	N/A	$0.36 per share	3.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
IMDX Oncocyte	-$50.22M	-$1.49	N/A	N/A	N/A	-2,955.63%	N/A	-107.52%	N/A
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)

Latest CELU, HURA, IMDX, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/10/2026	Q2 2026	IMDX Oncocyte	N/A	-$0.23	N/A	-$0.31	N/A	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IMDX Oncocyte	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.15	0.15
HURA TuHURA Biosciences	0.20	0.18	0.18
IMDX Oncocyte	N/A	2.00	1.98
INO Inovio Pharmaceuticals	N/A	1.00	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
HURA TuHURA Biosciences	0.62%
IMDX Oncocyte	55.35%
INO Inovio Pharmaceuticals	26.79%

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
HURA TuHURA Biosciences	6.06%
IMDX Oncocyte	2.21%
INO Inovio Pharmaceuticals	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	115	28.95 million	23.94 million	Optionable
HURA TuHURA Biosciences	22	63.73 million	59.87 million	N/A
IMDX Oncocyte	58	32.72 million	32.00 million	N/A
INO Inovio Pharmaceuticals	112	103.40 million	101.64 million	Optionable

CELU, HURA, IMDX, and INO Headlines

Recent News About These Companies

Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?

September 24, 2026 | finance.yahoo.com

Inovio Pharmaceuticals stock trades lower as FDA date nears

September 23, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals stock gains as price crosses 200-day moving average

September 19, 2026 | ad-hoc-news.deA

Inovio Pharmaceuticals (NASDAQ:INO) Stock Price Crosses Above 200-Day Moving Average - Here's What Happened

September 19, 2026 | americanbankingnews.com

Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above 200 Day Moving Average - Here's Why

September 19, 2026 | marketbeat.com

Inovio Pharmaceuticals stock trades near 52-week midpoint as analysts keep Moderate Buy view

September 18, 2026 | ad-hoc-news.deA

Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?

September 14, 2026 | finance.yahoo.com

Bet on 4 Top-Ranked Stocks With Rising P/E

September 14, 2026 | zacks.com

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript

September 11, 2026 | seekingalpha.com

Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms

September 11, 2026 | marketbeat.com

Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?

September 10, 2026 | finance.yahoo.com

Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP

September 10, 2026 | marketbeat.com

Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9, 2026 | seekingalpha.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Bet on 5 Top-Ranked Stocks With Rising P/E

September 3, 2026 | zacks.com

INOVIO to Participate in Upcoming Investor Conferences

September 1, 2026 | finance.yahoo.com

INOVIO to Participate in Upcoming Investor Conferences

September 1, 2026 | prnewswire.com

Inovio Pharmaceuticals (NASDAQ:INO) Shares Cross Above Two Hundred Day Moving Average - Here's What Happened

September 1, 2026 | marketbeat.com

Inovio: The Final Countdown To A Binary FDA Decision

August 25, 2026 | seekingalpha.com

Inovio (INO) Q2 2026 Earnings Call Transcript

August 13, 2026 | theglobeandmail.com

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, HURA, IMDX, and INO Company Descriptions

Celularity NASDAQ:CELU

$1.38 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.38 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

TuHURA Biosciences NASDAQ:HURA

$2.10 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.10 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Oncocyte NASDAQ:IMDX

$3.92 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$3.91 -0.01 (-0.26%)

As of 09/25/2026 07:30 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.18 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.01 (+0.42%)

As of 09/25/2026 07:38 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELU, HURA, IMDX, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELU, HURA, IMDX, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELU, HURA, IMDX, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, HURA, IMDX, and INO Company Descriptions

Celularity NASDAQ:CELU

TuHURA Biosciences NASDAQ:HURA

Oncocyte NASDAQ:IMDX

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CELU, HURA, IMDX, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CELU, HURA, IMDX, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CELU, HURA, IMDX, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, HURA, IMDX, and INO Company Descriptions

Celularity NASDAQ:CELU

TuHURA Biosciences NASDAQ:HURA

Oncocyte NASDAQ:IMDX

Inovio Pharmaceuticals NASDAQ:INO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools